scholarly journals Implications of Long-Term Survival in Acute Stem Cell Leukemia of Childhood Treated with Composite Cyclic Therapy

Blood ◽  
1964 ◽  
Vol 24 (5) ◽  
pp. 477-494 ◽  
Author(s):  
WOLF W. ZUELZER

Abstract The results of 9 years’ experience with acute stem cell (lymphoblastic) leukemia treated with a combination of steroids and antimetabolites, designated as "composite cyclic therapy" (CCT), are described and their theoretical implications are discussed. In 175 patients surviving at least one month after diagnosis the per cent survivals were: 17.2 months (50 per cent), 27.5 months (25 per cent), and 45.0 months (10 per cent). Six patients were alive in uninterrupted remission at the close of the study, from 4-9 years after diagnosis. The mean survival of the expired patients was 17.7 months, with a median of 14.5 months. The mean duration of the first remission was 15.2 months with a median of 12.5. The therapeutic response in terms of remission rate and total survival was significantly better in stem cell leukemia, as defined cytologically at the time of original diagnosis, than in other types, suggesting that the effect of steroids on the former is at least in part specific for malignant cells of lymphoid origin. A highly significant difference within the group of stem cell leukemia was observed between patients with initially low as compared to high white blood count, the dividing line being at 20,000 cells/mm.,3 the latter having twice the mean survival of the former. Of the 44 patients achieving survival of 2 years or more only one had an initial white count of more than 20,000. In conjunction with chromosome studies published elsewhere these findings suggest that the initial white count is a parameter, possibly of immunologic nature, indicative of the partial retention or complete loss of control over leukemic mutant cells. The possibility is discussed, on the basis of theoretical considerations and the observed role of long first remissions in the total survival time, that conditions and measures taken in the early stages of therapy may be decisive for the ultimate course. The current evidence for the mutational nature of acute leukemia permits the theoretical distinction between remission as the temporary suppression of a mutant stem line as opposed to a "cure" representing its permanent elimination, and to explain occasional apparent cures, including some observed in the present series, on that basis. Clinically, combined cyclic therapy or CCT appears to be superior to the use of single antimetabolites. The withholding of steroids until these drugs become ineffective does not at present appear justified.

Author(s):  
Sini Luoma ◽  
Raija Silvennoinen ◽  
Auvo Rauhala ◽  
Riitta Niittyvuopio ◽  
Eeva Martelin ◽  
...  

AbstractThe role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple myeloma is controversial. We analyzed the results of 205 patients transplanted in one center during 2000–2017. Transplantation was performed on 75 patients without a previous autologous SCT (upfront-allo), on 74 as tandem transplant (auto-allo), and on 56 patients after relapse. Median overall survival (OS) was 9.9 years for upfront-allo, 11.2 years for auto-allo, and 3.9 years for the relapse group (p = 0.015). Progression-free survival (PFS) was 2.4, 2.4, and 0.9 years, respectively (p < 0.001). Non-relapse mortality at 5 years was 8% overall, with no significant difference between the groups. Post-relapse survival was 4.1 years for upfront-allo and auto-allo, and 2.6 years for the relapse group (p = 0.066). Survival of high-risk patients was reduced. In multivariate analysis, the auto-allo group had improved OS and chronic graft-versus-host disease was advantageous in terms of PFS, OS, and relapse incidence. Late relapses occurred in all groups. Allo-SCT resulted in long-term survival in a small subgroup of patients. Our results indicate that auto-allo-SCT is feasible and could be considered for younger patients in the upfront setting.


Genomics ◽  
2019 ◽  
Vol 111 (6) ◽  
pp. 1566-1573 ◽  
Author(s):  
Jeane Silva ◽  
Chang-Sheng Chang ◽  
Tianxiang Hu ◽  
Haiyan Qin ◽  
Eiko Kitamura ◽  
...  

2019 ◽  
Vol 146 (8) ◽  
pp. 2243-2254
Author(s):  
Yating Chong ◽  
Yun Liu ◽  
Sumin Lu ◽  
Baohuan Cai ◽  
Haiyan Qin ◽  
...  

2012 ◽  
Vol 76 (11) ◽  
pp. 2118-2123 ◽  
Author(s):  
Ahmed Magzoub KHALID ◽  
Atsushi ASANO ◽  
Yoshinao Z. HOSAKA ◽  
Masanori OHTA ◽  
Kenji OHYAMA ◽  
...  

Blood ◽  
2004 ◽  
Vol 103 (9) ◽  
pp. 3249-3250
Author(s):  
Malcolm A. S. Moore

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3948-3948
Author(s):  
Oznur Yilmaz ◽  
Cetin Timur ◽  
Asim Yoruk ◽  
Muferet Erguven ◽  
Elif Aktekin ◽  
...  

Abstract In this study, we aimed to investigate epidemiologic factors in children with Acute Lymphoblastic leukemia (ALL). The parents of 105 children diagnosed and treated as ALL between the years 1997 –2007 in our Clinic of Pediatric Hematology-Oncology were questioned and results were compared with control group that consisted of 102 healthy children with similar age and gender. The mean age of the patients was 8.57 ± 3.95 years. The mean age at diagnosis was 5.87 ± 3.73 years. There was no significant difference between the groups in terms of type of delivery, birth weight, asphyxia at birth, resuscitation with high-concentration oxygen and ventilatory support (p&gt;0.05). There was also no significant difference between the groups in terms of duration of breast feeding. The rate of exposure to infections prior to diagnosis was higher in control group (p:0.003). Besides that, the rate of going to nursery was also significantly higher in control group (p:0.014). There was no difference between the groups in terms of X-ray exposure (p&gt;0.05). In conclusion over-protection from infectious agents in and delay in meeting with some specific agents seems to increase ALL risk. Infections in early infantile period can be protective against leukemia. There has to be more extended studies on this subject.


2009 ◽  
Vol 62 (5) ◽  
pp. 350-351 ◽  
Author(s):  
Hirokazu Murakami ◽  
Nahoko Hatsumi ◽  
Takayuki Saitoh ◽  
Takeki Mitsui ◽  
Takafumi Matsushima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document